Id |
Subject |
Object |
Predicate |
Lexical cue |
T7 |
0-15 |
Sentence |
denotes |
1 Introduction |
T8 |
16-169 |
Sentence |
denotes |
Coronavirus disease 2019 (COVID-19), which emerged in December 2019, is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. |
T9 |
170-325 |
Sentence |
denotes |
According to the World Health Organization (WHO), COVID-19 has resulted in 34 495 176 laboratory-confirmed cases and 1 025 729 deaths as of 3 October 2020. |
T10 |
326-415 |
Sentence |
denotes |
SARS-CoV-2 shares at least 70% similarity of its genetic sequence with SARS-CoV [1], [2]. |
T11 |
416-687 |
Sentence |
denotes |
Coming after SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), the SARS-CoV-2 outbreak is the third in a series of coronavirus outbreaks that have elicited heterogeneous clinical manifestations, ranging from asymptomatic response to fatal illness [3]. |
T12 |
688-970 |
Sentence |
denotes |
Like other common respiratory viruses (i.e., influenza virus, parainfluenza virus, respiratory syncytial virus, and rhinovirus), coronaviruses generally cause mild and self-limited upper respiratory tract infections with clinical manifestations of common cold or mild pneumonia [4]. |
T13 |
971-1073 |
Sentence |
denotes |
Among all known coronavirus species, only six have been identified to cause human diseases as of 2019. |
T14 |
1074-1202 |
Sentence |
denotes |
The 229E, OC43, NL63, and HKU1 coronaviruses are well documented and mostly result in mild-to-moderate respiratory diseases [5]. |
T15 |
1203-1499 |
Sentence |
denotes |
However, the substantial genetic diversity, frequent recombination, and cumulative mutations of their RNA genomes, along with the notable increase in human-to-wildlife activities, have collectively resulted in a greater likelihood of the emergence of more transmissible and/or virulent pathogens. |
T16 |
1500-1751 |
Sentence |
denotes |
Since the prevalence of COVID-19, China has been confronted with various uncertainties, including the infectivity and routes of transmission, clinical manifestations and immune responses, and possible effective treatments against SARS-CoV-2 infection. |
T17 |
1752-2021 |
Sentence |
denotes |
Determining how to best manage the surge of new cases, promptly triage patients based on the predicted disease development trajectory, and deploy practical management to improve the clinical outcomes has become the central task for the government and medical community. |
T18 |
2022-2309 |
Sentence |
denotes |
During the battle against COVID-19, based on the “life supremacy” policy, China has enforced rapid non-pharmaceutical interventions and played a crucial role in unraveling the viral transmission and clinical characteristics, and in developing novel therapeutic interventions and vaccine. |
T19 |
2310-2528 |
Sentence |
denotes |
Here, we summarize the strategies that have been used in China in different domains, which might help to increase our preparedness against future outbreaks and inform disease prevention and management across the globe. |